Literature DB >> 10070046

Diazepam-binding inhibitor33-50 elicits Ca2+ oscillation and CCK secretion in STC-1 cells via L-type Ca2+ channels.

H Yoshida1, Y Tsunoda, C Owyang.   

Abstract

We recently isolated and characterized 86-amino acid CCK-releasing peptide from porcine intestinal mucosa. The sequence of this peptide is identical to that of porcine diazepam-binding inhibitor (DBI). Intraduodenal administration of DBI stimulates the CCK release and elicits pancreatic secretion in rats. In this study we utilized a murine tumor cell line (STC-1 cells) that contains CCK to examine if DBI directly acts on these cells to stimulate CCK release. We investigated the cellular mechanisms responsible for this action. We showed that DBI33-50, a biologically active fragment of DBI1-86, significantly stimulated CCK secretion in STC-1 cells. This action was abolished by Ca2+-free medium. The mean basal intracellular Ca2+ concentration ([Ca2+]i) was 52 nM in fura 2-loaded STC-1 cells. DBI33-50 (1-1,000 nM) elicited Ca2+ oscillations; DBI33-50 (10 nM) increased the oscillation frequency to 5 cycles/10 min and elicited a net [Ca2+]i increase (peak - basal) to 157 nM. In contrast, bombesin and forskolin caused an initial transient [Ca2+]i followed by a small sustained [Ca2+]i plateau. Withdrawal of extracellular Ca2+ abolished Ca2+ oscillations stimulated by DBI33-50. L-type Ca2+ channel blockers nifedipine and diltiazem (3-10 microM) markedly attenuated DBI-stimulated Ca2+ oscillations. In other cell types L-type Ca2+ channels are activated by cAMP-protein kinase A. DBI33-50 failed to stimulate cAMP formation in STC-1 cells. Similarly, DBI33-50 had no effect on myo-inositol 1,4, 5-trisphosphate concentration ([IP3]), whereas bombesin caused an eightfold increase in [IP3] over basal. In addition, inhibitors of phospholipase C (U-73122), phospholipase A2 (ONO-RS-082), and protein tyrosine kinase (genistein) did not alter the Ca2+ oscillations elicited by DBI33-50. It appears that DBI33-50 acts directly on STC-1 cells to elicit Ca2+ oscillations via the voltage-dependent L-type Ca2+ channels, resulting in the secretion of CCK. Mediation of this action is by intracellular mechanisms independent of the traditional signal transduction pathways, including phospholipase C, phospholipase A2, protein tyrosine kinase, and cAMP systems.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10070046     DOI: 10.1152/ajpgi.1999.276.3.G694

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  6 in total

1.  Protein hydrolysate-induced cholecystokinin secretion from enteroendocrine cells is indirectly mediated by the intestinal oligopeptide transporter PepT1.

Authors:  Alice P Liou; Diana I Chavez; Elvis Espero; Shuzhen Hao; Stephen A Wank; Helen E Raybould
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-02-10       Impact factor: 4.052

2.  Diazepam-binding inhibitor mediates feedback regulation of pancreatic secretion and postprandial release of cholecystokinin.

Authors:  Y Li; Y Hao; C Owyang
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

3.  Cefaclor, a cephalosporin antibiotic, delays gastric emptying rate by a CCK-A receptor-mediated mechanism in the rat.

Authors:  A Bozkurt; M Deniz; B C Yegen
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

Review 4.  Astrocytes: GABAceptive and GABAergic Cells in the Brain.

Authors:  Jianhui Liu; Xuanran Feng; Yi Wang; Xiaohuan Xia; Jialin C Zheng
Journal:  Front Cell Neurosci       Date:  2022-06-10       Impact factor: 6.147

Review 5.  From benzodiazepines to fatty acids and beyond: revisiting the role of ACBP/DBI.

Authors:  Thierry Alquier; Catherine A Christian-Hinman; Julieta Alfonso; Nils J Færgeman
Journal:  Trends Endocrinol Metab       Date:  2021-09-23       Impact factor: 12.015

Review 6.  Protein Digestion-Derived Peptides and the Peripheral Regulation of Food Intake.

Authors:  Juliette Caron; Dorothée Domenger; Pascal Dhulster; Rozenn Ravallec; Benoit Cudennec
Journal:  Front Endocrinol (Lausanne)       Date:  2017-04-24       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.